Free tool
FAERS Monitor: Bendamustine Hydrochloride
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215033 or its brand name (Bendamustine Hydrochloride, Bendamustine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
7,951
Serious
7,612
96% of reports
Hospitalization
3,238
Death reported
1,554
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use995
- pyrexia555
- disease progression510
- covid-19406
- product use in unapproved indication400
- drug ineffective392
- febrile neutropenia366
- malignant neoplasm progression362
- neutrophil count decreased354
- neutropenia344
- platelet count decreased342
- pneumonia341
- anaemia321
- myelosuppression276
- prescribed underdose271
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 15 |
| 2012 | 129 |
| 2013 | 46 |
| 2014 | 267 |
| 2015 | 423 |
| 2016 | 435 |
| 2017 | 400 |
| 2018 | 594 |
| 2019 | 583 |
| 2020 | 607 |
| 2021 | 731 |
| 2022 | 1,445 |
| 2023 | 1,011 |
| 2024 | 735 |
| 2025 | 294 |
| 2026 | 230 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,208 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| prescribed underdoseSignal | 271 | 36.4 | 32.4 | 9,181 |
| neutrophil count decreasedSignal | 354 | 23.2 | 20.9 | 7,436 |
| myelosuppressionSignal | 276 | 20.4 | 18.2 | 5,048 |
| febrile neutropeniaSignal | 366 | 14.7 | 13.3 | 4,638 |
| disease progressionSignal | 510 | 11.4 | 10.5 | 4,858 |
| malignant neoplasm progressionSignal | 362 | 9.4 | 8.5 | 2,706 |
| platelet count decreasedSignal | 342 | 8.5 | 7.7 | 2,264 |
| neutropeniaSignal | 344 | 6.7 | 6.0 | 1,671 |
| covid-19Signal | 406 | 6.1 | 5.6 | 1,750 |
| anaemiaSignal | 321 | 4.5 | 4.0 | 864 |
| product use in unapproved indicationSignal | 400 | 4.3 | 3.9 | 1,010 |
| pyrexiaSignal | 555 | 4.2 | 3.9 | 1,396 |
| off label useSignal | 995 | 3.0 | 2.8 | 1,388 |
| pneumoniaSignal | 341 | 2.8 | 2.5 | 395 |
| drug ineffective | 392 | 0.8 | 0.7 | 24 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.